Herpes Zoster in a Patient with Ulcerative Colitis after Vedolizumab Initiation-Causal Link or Only Temporal Coincidence?

Na Wu,Hua Li,Jinyan Zhang,Weifeng Huang

DOI: https://doi.org/10.1093/ibd/izab229

2021-01-01

Inflammatory Bowel Diseases

Abstract:To the Editors, Herpes zoster results from the reactivation of latent varicella-zoster virus (VZV) in the cranial nerve or the dorsal root ganglia, with a higher rate in older persons or immunocompromised patients. Here, we report a case of herpes zoster eruption following the first dose of vedolizumab infusions in a 47-year-old man diagnosed with ulcerative colitis (UC). Previously, sulfasalazine and mesalazine failed to control UC activity in this patient. Given that no contraindications were found, vedolizumab was commenced in June 2021, with the patient also on mesalazine. Until this point, he had no previous episodes of herpes zoster eruption. However, 4 days after the first administration of vedolizumab, the patient developed a sore throat. On day 9 following the apparition of symptoms, scattered lesions on the right scapular area, right forearm, and fingers appeared, characterized by closely grouped papules and vesicles (Figure 1). The rash was preceded...